CLRB News and Press, Cellectar Biosciences Inc. From 05/15/19

Gainers : PDS Biotechnology (NASDAQ: PDSB ) +35% . Navios Maritime Holdings (NYSE: NM ) +26% . Cellectar Biosciences (NASDAQ: CLRB ) +21% . Nordic American Tankers (NYSE: NAT ) +14% . Ocean Bio-Chem (NASDAQ: OBCI ) +13% . Genetic Technologies (NASDAQ: GENE ) +13% . Amdocs (NASDAQ: DO...

Thinly traded nano cap Cellectar Biosciences ( CLRB +30.7% ) is up on a robust 32x surge in volume in reaction to preliminary data from Cohort 6 in its Phase 1 study of CLR 131 in patients with relapsed/refractory multiple myeloma. More news on: Cellectar Biosciences, Inc., Healthcare ...

Appliance Recycling Centers of America (NASDAQ: ARCI ) +19%  on Q1 earnings . More news on: Appliance Recycling Centers of America, Inc., PDS Biotechnology Corporation, The Container Store Group, Inc., Stocks on the move, Read more ...

Results demonstrated 50% partial response rate, 50% minimal response rate, and 100% disease control rate Independent Data Monitoring Committee determines dose to be safe and well tolerated and recommends study continue to Cohort 7 FLORHAM PARK, N.J., May 15, 2019 (GLOBE NEWSWIRE) -...

Gainers:  Cellectar Biosciences (NASDAQ: CLRB ) +7% . More news on: Cellectar Biosciences, Inc., INSYS Therapeutics, Inc., Soliton, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Thinly traded nano cap Cellectar Biosciences ( CLRB +5.6% ) is up on more than a 4x surge in volume on the heels of Fast Track status in the U.S. for lead candidate CLR 131 for the fourth line (or greater) treatment of relapsed/refractory multiple myeloma. More news on: Cellectar Biosc...

Amber Road (NYSE: AMBR ) +26%  on being acquired by E2open. More news on: Amber Road, Inc., Onconova Therapeutics, Inc., Catalyst Pharmaceuticals, Inc., Stocks on the move, Read more ...

FLORHAM PARK, N.J., May 13, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the U.S. Food and Drug Admi...

Cellectar Biosciences (NASDAQ: CLRB ): Q1 GAAP EPS of -$0.76  misses by $0.26 . Cash and cash equivalents of $10.48M Press Release More news on: Cellectar Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, ,

Reported positive top-line results from relapsed/refractory multiple myeloma cohort in ongoing Phase 2 clinical study of CLR 131 Announced median overall survival rate of 22 months in Cohorts 1-4 in its ongoing Phase 1 clinical study of CLR 131 in relapsed/refractory multiple myeloma ...